# Study to Evaluate the Safety and Tolerability of EP0042

> **NCT04581512** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ellipses Pharma** · enrollment: 70 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** EP0042
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine (AZA)

## Key facts

- **NCT ID:** NCT04581512
- **Lead sponsor:** Ellipses Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-02
- **Primary completion:** 2025-10
- **Final completion:** 2026-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04581512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04581512, "Study to Evaluate the Safety and Tolerability of EP0042". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04581512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*